A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...

全面介紹

書目詳細資料
發表在:International Journal of Tuberculosis and Lung Disease
主要作者: Tweed C.D.; Wills G.H.; Crook A.M.; Amukoye E.; Balanag V.; Ban A.Y.L.; Bateson A.L.C.; Betteridge M.C.; Brumskine W.; Caoili J.; Chaisson R.E.; Cevik M.; Conradie F.; Dawson R.; del Parigi A.; Diacon A.; Everitt D.E.; Fabiane S.M.; Hunt R.; Ismail A.I.; Lalloo U.; Lombard L.; Louw C.; Malahleha M.; McHugh T.D.; Mendel C.M.; Mhimbira F.; Moodliar R.N.; Nduba V.; Nunn A.J.; Sabi I.; Sebe M.A.; Selepe R.A.P.; Staples S.; Swindells S.; van Niekerk C.H.; Variava E.; Spigelman M.; Gillespie S.H.
格式: Article
語言:English
出版: International Union Against Tuberculosis and Lung Disease 2021
在線閱讀:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103500407&doi=10.5588%2fIJTLD.20.0513&partnerID=40&md5=8c765dc0d897b2fc30f93aff84366e37

因特網

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103500407&doi=10.5588%2fIJTLD.20.0513&partnerID=40&md5=8c765dc0d897b2fc30f93aff84366e37

相似書籍